A contactless cure : Leveraging telehealth to improve hepatitis C treatment at a safety-net hospital
© 2024 John Wiley & Sons Ltd..
Hepatitis C virus (HCV) causes significant mortality worldwide. HCV is highly curable but access to care is limited for many patients. The Grady Liver Clinic (GLC), a primary care-based HCV clinic, utilizes a multidisciplinary team to provide comprehensive care for a medically underserved patient population in Atlanta, Georgia. The GLC added a telehealth option for HCV treatment at the start of the COVID-19 pandemic. We describe the outcomes of utilizing telehealth in this population. We performed a retrospective chart review of patients who initiated HCV treatment from March 2019 to February 2020 (pre-pandemic) and March 2020 to February 2021 (pandemic). Charts were abstracted for patient demographics and characteristics, treatment regimen, and treatment outcomes. Our primary outcome was HCV cure rate of the pre-pandemic compared to the pandemic cohorts and within the different pandemic cohort visit types. We performed an intention-to-treat (ITT) analysis for all patients who took at least one dose of a direct-acting antiviral (DAA) regardless of therapy completion, and a per-protocol (PP) analysis of those who completed treatment and were tested for HCV cure. SVR12 rates were >95% on ITT analysis, with no significant difference between pre-pandemic and pandemic cohorts. There was also no significant difference within the pandemic group when treatment was provided traditionally, via telehealth, or via a hybrid of these. Our findings support the use of telehealth as a tool to expand access to HCV treatment in a medically underserved patient population.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:31 |
|---|---|
| Enthalten in: |
Journal of viral hepatitis - 31(2024), 4 vom: 16. Apr., Seite 176-180 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Frye, Krysta [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antiviral Agents |
|---|
| Anmerkungen: |
Date Completed 18.03.2024 Date Revised 17.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/jvh.13913 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368597520 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368597520 | ||
| 003 | DE-627 | ||
| 005 | 20240417232518.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240219s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/jvh.13913 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1378.xml |
| 035 | |a (DE-627)NLM368597520 | ||
| 035 | |a (NLM)38369695 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Frye, Krysta |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A contactless cure |b Leveraging telehealth to improve hepatitis C treatment at a safety-net hospital |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.03.2024 | ||
| 500 | |a Date Revised 17.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 John Wiley & Sons Ltd. | ||
| 520 | |a Hepatitis C virus (HCV) causes significant mortality worldwide. HCV is highly curable but access to care is limited for many patients. The Grady Liver Clinic (GLC), a primary care-based HCV clinic, utilizes a multidisciplinary team to provide comprehensive care for a medically underserved patient population in Atlanta, Georgia. The GLC added a telehealth option for HCV treatment at the start of the COVID-19 pandemic. We describe the outcomes of utilizing telehealth in this population. We performed a retrospective chart review of patients who initiated HCV treatment from March 2019 to February 2020 (pre-pandemic) and March 2020 to February 2021 (pandemic). Charts were abstracted for patient demographics and characteristics, treatment regimen, and treatment outcomes. Our primary outcome was HCV cure rate of the pre-pandemic compared to the pandemic cohorts and within the different pandemic cohort visit types. We performed an intention-to-treat (ITT) analysis for all patients who took at least one dose of a direct-acting antiviral (DAA) regardless of therapy completion, and a per-protocol (PP) analysis of those who completed treatment and were tested for HCV cure. SVR12 rates were >95% on ITT analysis, with no significant difference between pre-pandemic and pandemic cohorts. There was also no significant difference within the pandemic group when treatment was provided traditionally, via telehealth, or via a hybrid of these. Our findings support the use of telehealth as a tool to expand access to HCV treatment in a medically underserved patient population | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a chronic disease | |
| 650 | 4 | |a hepatitis C | |
| 650 | 4 | |a telemedicine | |
| 650 | 4 | |a urban population | |
| 650 | 4 | |a vulnerable populations | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 700 | 1 | |a Davis, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Darby, Rapheisha |e verfasserin |4 aut | |
| 700 | 1 | |a McDaniel, Kathryn |e verfasserin |4 aut | |
| 700 | 1 | |a Quairoli, Kristi |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Zhanxu |e verfasserin |4 aut | |
| 700 | 1 | |a Miller, Lesley S |e verfasserin |4 aut | |
| 700 | 1 | |a Fluker, Shelly-Ann |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of viral hepatitis |d 1997 |g 31(2024), 4 vom: 16. Apr., Seite 176-180 |w (DE-627)NLM074659642 |x 1365-2893 |7 nnns |
| 773 | 1 | 8 | |g volume:31 |g year:2024 |g number:4 |g day:16 |g month:04 |g pages:176-180 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/jvh.13913 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 31 |j 2024 |e 4 |b 16 |c 04 |h 176-180 | ||